Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Open-label Trial Assessing Sacituzumab-govitecan and Trastuzumab-deruxtecan Combinations in an Alternating Regimen for Patients With Metastatic or Locally Advanced HER2-low Triple-negative Breast Cancer

NCT07151586 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT07151586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07151586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Open-label Trial Assessing Sacituzumab-govitecan and Trastuzumab-deruxtecan Combinations in an Alternating Regimen for Patients With Metastatic or Locally Advanced HER2-low Triple-negative Breast Cancer
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
October 31, 2029
Enrollment
260 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

her 2 low-expressing breast cancer, neoplasm metastasis, triple negative breast neoplasms